Detail akcie Zura Bio Rg-A online

Business Summary: Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Zura Bio Ltd revenues was not reported. Net loss applicable to common stockholders increased 47% to $53.5M. Higher net loss reflects Research and development - Balancing val increase from $13.3M to $29.7M (expense), General and administrative - Balancing v increase of 43% to $17.4M (expense), Interest income decrease of 14% to $5.1M (income).